-
Something wrong with this record ?
Epigenetic alterations of testicular germ cell tumours
D. Ilijazi, SF. Shariat, MR. Hassler, U. Lemberger, IE. Ertl,
Language English Country United States
Document type Journal Article, Review
- MeSH
- Antineoplastic Agents therapeutic use MeSH
- Azacitidine analogs & derivatives therapeutic use MeSH
- Azepines therapeutic use MeSH
- Cinnamates therapeutic use MeSH
- Epigenesis, Genetic genetics MeSH
- Neoplasms, Germ Cell and Embryonal drug therapy genetics MeSH
- Imidazoles therapeutic use MeSH
- Humans MeSH
- DNA Methylation genetics MeSH
- MicroRNAs genetics MeSH
- Biomarkers, Tumor genetics MeSH
- RNA, Untranslated genetics MeSH
- Testicular Neoplasms drug therapy genetics MeSH
- Triazoles therapeutic use MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) exhibit, in contrast to other cancer types, a relatively low mutational burden. However, numerous epigenetic alterations have been shown to impact TGCT. In this review, we summarize the most relevant findings of the past 2 years. RECENT FINDINGS: Recent studies focused on the functions of microRNAs and the impact of aberrant DNA methylation. Moreover, several epigenetic drugs with antineoplastic effects in TGCTs were identified. SUMMARY: Aberrant DNA methylation and differentially expressed microRNAs have an important effect on TGCT pathogenesis. Moreover, differential DNA methylation patterns were found to be specific for different TGCT subtypes. Various microRNAs, such as miR-371a-3p, were found to be highly sensitive and specific biomarkers for TGCT. The epigenetic drugs guadecitabine, animacroxam, and JQ1 showed promising effects on TGCT in preclinical in-vivo and in-vitro studies.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025162
- 003
- CZ-PrNML
- 005
- 20201222155106.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000724 $2 doi
- 035 __
- $a (PubMed)31905176
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ilijazi, Dafina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 245 10
- $a Epigenetic alterations of testicular germ cell tumours / $c D. Ilijazi, SF. Shariat, MR. Hassler, U. Lemberger, IE. Ertl,
- 520 9_
- $a PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) exhibit, in contrast to other cancer types, a relatively low mutational burden. However, numerous epigenetic alterations have been shown to impact TGCT. In this review, we summarize the most relevant findings of the past 2 years. RECENT FINDINGS: Recent studies focused on the functions of microRNAs and the impact of aberrant DNA methylation. Moreover, several epigenetic drugs with antineoplastic effects in TGCTs were identified. SUMMARY: Aberrant DNA methylation and differentially expressed microRNAs have an important effect on TGCT pathogenesis. Moreover, differential DNA methylation patterns were found to be specific for different TGCT subtypes. Various microRNAs, such as miR-371a-3p, were found to be highly sensitive and specific biomarkers for TGCT. The epigenetic drugs guadecitabine, animacroxam, and JQ1 showed promising effects on TGCT in preclinical in-vivo and in-vitro studies.
- 650 _2
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a azacytidin $x analogy a deriváty $x terapeutické užití $7 D001374
- 650 _2
- $a azepiny $x terapeutické užití $7 D001381
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a cinnamáty $x terapeutické užití $7 D002934
- 650 _2
- $a metylace DNA $x genetika $7 D019175
- 650 _2
- $a epigeneze genetická $x genetika $7 D044127
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imidazoly $x terapeutické užití $7 D007093
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a germinální a embryonální nádory $x farmakoterapie $x genetika $7 D009373
- 650 _2
- $a nekódující RNA $x genetika $7 D022661
- 650 _2
- $a testikulární nádory $x farmakoterapie $x genetika $7 D013736
- 650 _2
- $a triazoly $x terapeutické užití $7 D014230
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Shariat, Shahrok F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Department of Urology, Weill Cornell Medical College, New York, New York. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 700 1_
- $a Hassler, Melanie R $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Lemberger, Ursula $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Ertl, Iris E $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 2 (2020), s. 264-270
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31905176 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155102 $b ABA008
- 999 __
- $a ok $b bmc $g 1599307 $s 1115848
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 2 $d 264-270 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20201125
